DDDouglas C. Dover

Douglas C. Dover

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Douglas C. Dover has a total of 68 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Outcomes and Patterns Related to Magnesium in Acute Heart Failure: A Population-Based Study

    by Robert Margaryan, Sunjidatul Islam, Douglas Douver, Finlay A. McAlister, Padma Kaul, Justin A. Ezekowitz

    Importance: The significance of magnesium as a treatment or prognostic factor is unknown in heart failure despite its frequent use. Objective: To assess the frequency and outcomes of magnesium testing, hypomagnesemia and intravenous (IV) replacement in a large population-based cohort. Design, Setting, and Participants: Retrospective cohort study using linked administrative data from April 2012 - March 2020. Patients with primary diagnosis of HF in the emergency department or hospital were included and the rates and outcomes of magnesium testing, hypomagnesemia and IV replacement were assessed. Main Outcome(s) and Measure(s): The primary clinical outcomes included all-cause and cause specific death and hospitalization. Secondary outcomes included emergency department visits and physicians claims. Other outcomes included factors and rates of serum magnesium testing and hypomagnesemia. Results: Of 78,957 acute heart failure episodes (in 42,763 patients), 58.7% included a serum magnesium measurement. Of the patients who were tested, serum magnesium levels were 0.95 mmol/L in 11.5%. Magnesium levels (per 0.02 mmol/L increase) were independently associated with mortality when <0.70 mmol/L [hazard ratio (HR) 0.99 (95% confidence interval (CI) 0.98-0.99); p0.86 mmol/L [HR 1.04 (95% CI 1.03-1.04); p<0.001]. IV magnesium was given to 13.7% (n=6,333) of those who were tested (29.7% of whom did not have hypomagnesemia); after multivariable adjustment, receiving IV magnesium was associated with a higher short term mortality [HR 1.66 (95% CI 1.4-1.96); p<0.0001] and hospitalization risk [HR 1.36 (95% CI 1.13-1.63); p<0.001]. Conclusions and Relevance: Serum magnesium testing is common in patients presenting to the ED or hospital with HF, and low or high magnesium is associated with worse outcomes. Replacement with IV magnesium was associated with worse outcomes even after adjustment, a finding which warrants further study.

  • Open Access

    Hyperkalemia-related Heart Failure Therapy Discontinuation and the Association with Outcomes in Patients with Heart Failure

    by Aanchel Gupta, Sunjidatul Islam, Douglas C. Dover, Padma Kaul, Finlay McAlister, Justin Ezekowitz

    Background: Renin-angiotensin-aldosterone system (RAAS) inhibitors are essential treatments for heart failure (HF) patients, but their use is often limited by hyperkalemia. Objective: This study assesses the incidence of hyperkalemia in chronic HF patients on RAAS inhibitors, examines changes in therapy following hyperkalemia episodes, and evaluates the impact of RAAS inhibitor discontinuation or down-titration on patient outcomes. Methods: We conducted a population-based cohort study of patients hospitalized or visiting the emergency department in Alberta for chronic HF from April 2012 to March 2020, focusing on those with RAAS inhibitor-associated hyperkalemia. Episodes of hyperkalemia (K >5.0 mmol/L) were monitored, and patients were followed for 30 days to determine if their RAAS therapy was maintained, reduced, or discontinued. Results: Among 7527 HF patients, we identified 123,038 RAAS inhibitor treatment years, resulting in 17 hyperkalemia events per 100 treatment years. Hyperkalemia led to RAAS inhibitor discontinuation in 35.2% of cases, down-titration in 8.4%, and continuation in 56.4%. Discontinuation or down-titration was more common when serum potassium exceeded 6.0 mmol/L (49.4%) compared to lower levels. Over a median follow-up of 1.4 years, discontinuing or down-titrating RAAS inhibitors was associated with increased all-cause mortality (aHR 1.80), higher cardiovascular hospitalizations (aHR 1.09), and more frequent ED visits for HF (aHR 1.17) compared to continued therapy. Conclusions: Discontinuation or down-titration of RAAS inhibitors in HF patients is associated with higher mortality and cardiovascular events. Strategies to maintain RAAS therapy after hyperkalemia episodes may improve patient outcomes.

  • Relationships Between Measures of the Physical Activity-Related Built Environment and Excess Weight in Preschoolers: A Retrospective, Population-Level Cohort Study

    by Jessica Wijesundera, Geoff D.C. Ball, Alexander J. Wray, Jason Gilliland, Anamaria Savu, Douglas C. Dover, Andrea M. Haqq, Padma Kaul

    Background: The built environment can impact health outcomes. Our purpose was to examine relationships between built environment variables related to physical activity and excess weight in preschoolers. Methods: In this retrospective, population-level study of 4- to 6-year-olds, anthropometric measurements were taken between 2009 and 2017 in Calgary and Edmonton, Alberta, Canada. Based on BMI z-scores (BMIz), children were classified as normal weight (−2 ≤ BMIz n = 69,454; Calgary: n = 84,101). For Calgary, adjusted odds ratios (aORs) showed the odds of excess weight increased 1% for every 100-intersection increase [1.010 (1.006–1.015); p < 0.0001] and 13.6% when there were ≥4 playgrounds (vs. 0 or 1) within an 800 m buffer zone [1.136 (1.037–1.243); p = 0.0059]. For Edmonton, aORs revealed lower odds of excess weight for every 100 m increase in distances between residences to nearest major park [0.991 (0.986–0.996); p = 0.0005] and school [0.992 (0.990–0.995); p < 0.0001]. The odds of excess weight decreased as the number of major parks within the 800 m buffer zone increased from 0 to 1 [0.943 (0.896–0.992); p = 0.023] and from 0 to ≥3 [0.879 (0.773–0.999); p = 0.048]. Conclusion: The physical activity-related built environment was associated with excess weight in preschoolers, although relationships varied between cities that differed demographically and geographically.

  • Open Access

    IMPACT OF THE COVID-19 PANDEMIC ON ADHERENCE TO CARDIOVASCULAR MEDICATIONS AMONG CHRONICALLY TREATED PATIENTS IN ALBERTA

    by Finlay A. McAlister, Anamaria Savu, Luan Manh Chu, Douglas C. Dover, Padma Kaul

    Background: Some studies have suggested that the COVID-19 pandemic negatively impacted patient adherence with chronic therapies. We designed this study to explore whether cardiovascular drug adherence patterns changed in chronically treated patients during the COVID-19 pandemic. Methods: Retrospective cohort study examining drug dispensation data for all Alberta residents older than 18 years who were chronic users of at least one cardiovascular drug class, defined as receiving at least one prescription per annum for any agent in that drug class from March 15, 2017 to March 14, 2023 and 2 or more prescriptions within 365 days during either the pre-pandemic phase (March 15, 2018 to March 14, 2020) or the pandemic phase (March 15, 2020 to March 14, 2022). We calculated the proportion of days covered (PDC) for each drug class per patient and used generalized estimating equation logistic regression to estimate the effect of time period (pandemic versus pre-pandemic) on achievement of good adherence (PDC>0.8) after adjusting for age, sex, socioeconomic status, and comorbidities. Results: We evaluated 548,601 chronic users of at least one cardiovascular drug class between March 15, 2018 and March 14, 2022. The most frequently dispensed cardiovascular drug classes were ACEi/ARB (67.6%), statins (53.8%), beta-blockers (21.0%), and calcium channel blockers (20.7%); the most frequent diagnoses were hypertension (77.2%), diabetes mellitus (30.6%), and ischemic heart disease (19.6%), although 55.4% of the patients had Charlson Comorbidity Index scores of 0. The mean PDC for cardiovascular drug use in our cohort was 85.7% (median 93%) pre-pandemic and 87.0% (median 94%) during the pandemic. The proportion exhibiting good adherence (PDC>0.8) increased from 72.8% pre-pandemic to 75.4% during the pandemic (p0.8) than they were in the pre-pandemic period: aOR ranged from 1.05 (95%CI 1.00-1.11) for mineralocorticoid receptor antagonists to 1.16 (1.15-1.17) for statins. Conclusion: Chronic users of cardiovascular drugs exhibited higher adherence measures during the COVID-19 pandemic than prior to the pandemic.


  • Open Access

    Association Between Hemoglobin A1c and Development of Cardiovascular Disease in Canadian Men and Women Without Diabetes at Baseline: A Population‐Based Study of 608 474 Adults

    by Sonia Butalia, Luan Manh Chu, Douglas C. Dover, Darren Lau, Roseanne O. Yeung, Dean T. Eurich, Peter Senior, Padma Kaul

    Background: We examined the association between hemoglobin A1c (HbA1c) and the development of cardiovascular disease (CVD) in men and women, without diabetes or CVD at baseline. Methods and Results: This retrospective cohort study included adults aged 40 to <80 years in Alberta, Canada. Men and women were divided into categories based on a random HbA1c during a 3‐year enrollment period. The primary outcome of CVD hospitalization and secondary outcome of combined CVD hospitalization/mortality were examined during a 5‐year follow‐up period until March 31, 2021. A total of 608 474 individuals (55.2% women) were included. Compared with HbA1c 5.0% to 5.4%, men with HbA1c of 5.5% to 5.9% had an increased risk of CVD hospitalization (adjusted hazard ratio [aHR], 1.12 [95% CI, 1.07–1.19]) whereas women did not (aHR, 1.01 [95% CI, 0.95–1.08]). Men and women with HbA1c of 6.0% to 6.4% had a 38% and 17% higher risk and men and women with HbA1c ≥6.5% had a 79% and 51% higher risk of CVD hospitalization, respectively. In addition, HbA1c of 6.0% to 6.4% and HbA1c ≥6.5% were associated with a higher risk (14% and 41%, respectively) of CVD hospitalization/death in men, but HbA1c ≥6.5% was associated with a 24% higher risk only among women. Conclusions: In both men and women, HbA1c ≥6.0% was associated with an increased risk of CVD and mortality outcomes. The association between CVD and HbA1c levels of 5.5% to 5.9%, considered to be in the “normal” range, highlights the importance of optimizing cardiovascular risk profiles at all levels of glycemia, especially in men.


  • Iron Deficiency, Anemia, and Iron Supplementation in Patients With Heart Failure: A Population-Level Study

    by Muizz Wahid, Sunjidatul Islam, Nariman Sepehrvand, Douglas C. Dover, Finlay A. McAlister, Padma Kaul, Justin A. Ezekowitz

    BACKGROUND: Studies have shown an association between iron deficiency (ID) and clinical outcomes in patients with heart failure (HF), irrespective of the presence of ID anemia (IDA). The current study used population-level data from a large, single-payer health care system in Canada to investigate the epidemiology of ID and IDA in patients with acute HF and those with chronic HF, and the iron supplementation practices in these settings. METHODS: All adult patients with HF in Alberta between 2012 and 2019 were identified and categorized as acute or chronic HF. HF subtypes were determined through echocardiography data, and ID (serum ferritin concentration <100 μg/L, or ferritin concentration between 100 and 300 μg/L along with transferrin saturation <20%), and IDA through laboratory data. Broad eligibility for 3 clinical trials (AFFIRM-AHF [Study to Compare Ferric Carboxymaltose With Placebo in Patients With Acute HF and ID], IRONMAN [Intravenous Iron Treatment in Patients With Heart Failure and Iron Deficiency], and HEART-FID [Randomized Placebocontrolled Trial of Ferric Carboxymaltose as Treatment for HF With ID]) was determined. RESULTS: Among the 17 463 patients with acute HF, 38.5% had iron studies tested within 30 days post-index-HF episode (and 34.2% of the 11 320 patients with chronic HF). Among tested patients, 72.6% of the acute HF and 73.9% of the chronic HF were iron-deficient, and 51.4% and 49.0% had IDA, respectively. Iron therapy was provided to 41.8% and 40.5% of patients with IDA and acute or chronic HF, respectively. Of ID patients without anemia, 19.9% and 21.7% were prescribed iron therapy. The most common type of iron therapy was oral (28.1% of patients). Approximately half of the cohort was eligible for each of the AFFIRM-AHF, intravenous iron treatment in patients with HF and ID, and HEART-FID trials. CONCLUSIONS: Current practices for investigating and treating ID in patients with HF do not align with existing guideline recommendations. Considering the gap in care, innovative strategies to optimize iron therapy in patients with HF are required.


  • Open Access

    Cardiovascular disease risk in males and females with new onset diabetes: a population-based study in universal health care setting

    by P Kaul, L Manh Chu, D C Dover, D T Eurich, R O Yeung, P Senior, S Butalia

    Background: The evidence on whether long-term cardiovascular disease (CVD) outcomes differ among males and females with incident diabetes remains equivocal. Objective: To examine sex-differences in the association between incident diabetes and 5-year risk of CVD and mortality at the population-level. Methods: The study population consisted of an inception cohort of individuals between 40 and 80 years without diabetes or CVD on April 1, 2013 in the province of Alberta, Canada (N=1,315,885). Incident diabetes during a 3-year period was used to categorize males and females by diabetes status as of March 31, 2016. Primary outcome of interest was a combination of CVD hospitalization (defined as a hospitalization with a primary diagnosis of heart failure, acute coronary syndromes, cerebrovascular disorders, atrial fibrillation and flutter, ventricular arrhythmia, or sudden cardiac death) or all-cause mortality over a 5-year period until March 31, 2021. Inverse probability of treatment weighting (IPTW) was used to reduce the impact of confounders between individuals with and without diabetes. Kaplan-Meier curves were used to examine unadjusted outcomes and Cox-proportional hazards models were used to examine the impact of diabetes on outcomes in males and females after adjusting for the following: age, hypertension, material deprivation, urban/rural residence, and comorbidity burden. Results: Among 672,881 females and 643,004 males, 27,082 (4.0%) and 33,054 (5.1%) developed incident diabetes, respectively. Regardless of sex, individuals with diabetes were older and had higher rates of hypertension and other comorbidities. Overall, CVD hospitalization/mortality rates per 1000 person years were 7.5% (95% confidence interval (CI): 7.4–7.6) among females compared to 11.7% (95% CI: 11.6–11.8) among males. When stratified by diabetes status, the rates of the combined endpoint were 7.2% (95% CI: 7.1–7.3) among females with no diabetes (F w/o DM), 11.2% (95% CI: 11.1–11.3) among males with no diabetes (M w/o DM), 14.7% (95% CI: 14.0–15.3) among females with diabetes (F with DM) and 20.9% (95% CI: 20.1–21.6) among males with diabetes (M with DM, Figure 1). The adjusted hazard ratio (aHR) associated with diabetes on outcomes was similar among males (aHR 1.38 95% confidence interval (CI): 1.36–1.41) and females (aHR 1.39 95% CI: 1.36–1.42). Conclusions: The presence of diabetes weakens the possible cardio-protection of female sex with respect to CVD outcomes. Future work aims to assess CVD prevention, management and treatment among males with females with incident diabetes. Funding Acknowledgement: Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Canadian Institutes of Health Research (CIHR) Sex and Gender Science Chair


  • Open Access

    Impact of Socioeconomic Status and Residence Distance on Infant Heart Disease Outcomes in Canada

    by Oluwayomi Olugbuyi, Christopher Smith, Padma Kaul, Douglas C. Dover, Andrew S. Mackie, Sunjidatul Islam, Luke Eckersley, Lisa K. Hornberger

    Background: Socioeconomic status (SES) impacts clinical outcomes associated with severe congenital heart disease (sCHD). We examined the impact of SES and remoteness of residence (RoR) on congenital heart disease (CHD) outcomes in Canada, a jurisdiction with universal health insurance. Methods and Results: All infants born in Canada (excluding Quebec) from 2008 to 2018 and hospitalized with CHD requiring intervention in the first year were identified. Neighborhood level SES income quintiles were calculated, and RoR was categorized as residing 300 km from the closest of 7 cardiac surgical programs. In‐hospital mortality at . 2%) had moderate CHD (mCHD) and 3226 (41.8%) had sCHD. Overall mortality rate was 10.5%, with higher rates in sCHD than mCHD (13.3% versus 8.5%, respectively). More CHD infants were in the lowest compared with the highest SES category (27.1% versus 15.0%, respectively). The distribution of CHD across RoR categories was 52.3%, 21.3%, and 26.4% for 300 km, respectively. Although SES and RoR had no impact on sCHD mortality, infants with mCHD living >300 km had a higher risk of mortality relative to those living <100 km (adjusted odds ratio [aOR], 1.43 [95% CI, 1.11–1.84]). Infants with mCHD within the lowest SES quintile and living farthest away had the highest risk for mortality (aOR, 1.74 [95% CI, 1.08–2.81]). Conclusions: In Canada, neither RoR nor SES had an impact on outcomes of infants with sCHD. Greater RoR, however, may contribute to higher risk of mortality among infants with mCHD.


  • Open Access

    Trends in Uptake and Adherence to Oral Anticoagulation for Patients With Incident Atrial Fibrillation at High Stroke Risk Across Health Care Settings

    by Haran Yogasundaram, Douglas C. Dover, Nathaniel M. Hawkins, Finlay A. McAlister, Shaun G. Goodman, Justin Ezekowitz, Padma Kaul, Roopinder K. Sandhu

    Background: Oral anticoagulation (OAC) therapy prevents morbidity and mortality in nonvalvular atrial fibrillation; whether location of diagnosis influences OAC uptake or adherence is unknown. Methods and Results: Retrospective cohort study (2008–2019), identifying adults with incident nonvalvular atrial fibrillation across health care settings (emergency department, hospital, outpatient) at high risk of stroke. OAC uptake and adherence via proportion of days covered for direct OACs and time in therapeutic range for warfarin were measured. Proportion of days covered was categorized as low (0–39%), intermediate (40–79%), and high (80–100%). Warfarin control was defined as time in therapeutic range ≥65%. All‐cause mortality was examined at a 3‐year landmark. Among 75 389 patients with nonvalvular atrial fibrillation (47.0% women, mean 77.4 years), 19.7% were diagnosed in the emergency department, 59.1% in the hospital, and 21.2% in the outpatient setting. Ninety‐day OAC uptake was 51.6% in the emergency department, 50.9% in the hospital, and 67.9% in the outpatient setting ( P P values for trend <0.0001). Warfarin control was 40.3% overall and remained unchanged. In multivariable analysis, outpatient diagnosis compared with the hospital was associated with greater OAC uptake (odds ratio [OR], 1.79; [95% CI, 1.72–1.87]) and direct OAC (OR, 1.42; [95% CI, 1.27–1.59]) and warfarin (OR, 1.49; [95% CI, 1.36–1.63]) adherence. Varying or persistently low adherence was associated with a poor prognosis, especially for warfarin. Conclusions: Locale of nonvalvular atrial fibrillation diagnosis is associated with varying OAC uptake and adherence. Interventions specific to health care settings are needed to improve stroke prevention.